Last reviewed · How we verify
NCT05060744: AQUAA
Efficacy and Speed of Action of a Product to Control Gastric Hydration and Gastroesophageal Reflux
NA trial testing Antacid in Oesophageal Reflux in 50 participants. Status unknown.
30 May 2023
Quick facts
| Lead sponsor | Uriach Consumer Healthcare |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 9 September 2021 |
| Primary completion | 30 May 2023 |
| Estimated completion | 30 June 2023 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Antacid
- Control
Conditions studied
- Oesophageal Reflux — all drugs for Oesophageal Reflux →
- Gastric Reflux — all drugs for Gastric Reflux →
- Hyperactivity; Stomach — all drugs for Hyperactivity; Stomach →
Sponsor
Uriach Consumer Healthcare
Who can join
18 and older, any sex, with Oesophageal Reflux or Gastric Reflux. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Randomised, Placebo-Controlled Clinical Trial off the Efficacy and Rapidity of Action of a Product Containing Sodium Alginate, Calcium and Magnesium Salts, Hyaluronic Acid and Aloe Vera to Control Oesophageal-Gastric pH and Reduce Symptoms of Gastric Reflux and Hyperacidity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05060744
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Antacid
Trials testing the same drug.
- NCT06503978 — Microbiota Transplant Therapy for Children With Both Autism Spectrum Disorder and Gastrointestinal Disorders · Phase 2 · active not recruiting
- NCT05028673 — A Study to Evaluate a New Tablet Formulation of Lu AG06466 in Healthy Participants · Phase 1 · completed
- NCT04265053 — Human Cerebral Blood Flow Regulation · EARLY_PHASE1 · completed
Other Uriach Consumer Healthcare trials
Trials by the same sponsor.
- NCT06199128 — Efficacy and Safety of Carboxymethyl Beta-glucan and Policarbophil in HPV Positive Patients · completed
- NCT05459272 — Clinical Trial on a Food Supplement With Melatonin and Herbal Products to Improve Sleep Quality · NA · unknown
- NCT04771546 — Efficacy of Intravaginal Carboxymethyl-β-glucan and Polycarbophil on Low-grade Cervical Lesions (GLUCANCIN) · NA · unknown
- NCT04781023 — Efficacy of an Intravaginal Treatment With Carboxymethyl-β-glucan and Polycarbophil in HR-HPV Clearance · NA · unknown
- NCT06324760 — Alpha-lipoic Acid Combined With B Vitamins Shows Promise for Treating Restless Legs Syndrome · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05060744 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Uriach Consumer Healthcare
- Last refreshed: 26 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05060744.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing